Chronic Obstructive Pulmonary Disease and Vascular Disease Delay Timeliness of Early Stage Lung Cancer Resectional Surgery

Figures & data

Table 1.  Baseline characteristics of NSCLC patients at NMCSD from 2004 to 2009*

Characteristic	Women	Men	Total
Patients	41	43	84
Age (year)	63 (59.7–68)	65 (63.5–68)	65 (63–67.5)
BMI	24 (23–26.3)	27 (26–30)	26 (24–27)
Non-smoker	18	6	24
Smoker	7	10	17
Ex-smoker	16	27	43
Race
Caucasian	17	32	49
African American	2	4	6
Asian/Pacific Islander	13	4	17
Other	9	2	11

*Values are given as number or median with 95% confidence interval.

Table 2.  Number of co-morbidities and timeliness of treatment in NSCLC patients

Number of Co-morbidity	N	CTS-OR* (days)	PUL-OR** (days)
0	19	21.5 (14.3–33.7)	57 (47.8–73)
58.5 (40–79.2)
1	36	20 (15–37.8)
2	17	26 (20–46.9)	49 (40.1–72.6)
126 (32–246)
3	6	47 (15.6–129.8)
4	4	48.5 (36–57)	180 (82–281)
5	0	0	0
6	2	85.5 (71–100)	218 (58–378)


*Median days with 95% confidence interval from Cardiothoracic Surgery (CTS) to thoractomy (OR).

**Median days with 95% confidence interval from Pulmonary evaluation (PUL) to thoractomy (OR).

Table 3.  Influence of different co-morbidity on the timeliness of treatment in NSCLC patients

		CTS-OR
Co-morbidity	N	Days*	P value**
None	19	21.5 (21–41)	–
Diabetes	22	21.5 (16–37)	0.605
Peripheral vascular disease	14	46.5 (27–74)	0.013
Coronary artery disease	15	39 (25–76)	0.018
Cerebral vascular disease	4	64 (46–100)	0.019
COPD	28	38 (21–54)	0.046
Sleep apnea	5	47 (6–62)	0.823
Liver Disease	5	55 (21–100)	0.070

*Median day with 95% confidence interval from cardiothoracic surgery (CTS) to thoractomy (OR).

**P-value comparing Timeliness of care between NSCLC Patients with no co-morbidity and NSCLC Patients with a defined co-morbidity. Patients with a defined co-morbidity (analyzed using rank-sum test). A probability value of less than 0.05 was considered statistically significant.